Related Experiment Videos
Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study
Tina Constantin1, Vin Tangpricha1,2, Reshma Shah1
1Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30307.
The Journal of Clinical Endocrinology and Metabolism
|April 14, 2017
Summary
Acromegaly alters calcium-phosphate levels and bone turnover, with increased bone resorption. Treatment normalized these markers, reducing bone resorption within six months.
Area of Science:
- Endocrinology
- Bone Metabolism
- Mineral Metabolism
Background:
- Acromegaly is linked to calcium-phosphate and bone turnover abnormalities.
- Controlled studies investigating these interactions are limited.
Purpose of the Study:
- To evaluate calcium and bone metabolism in patients with active and treated acromegaly.
- To assess changes in bone turnover markers and cytokines following acromegaly treatment.
Main Methods:
- A prospective study compared 22 acromegaly patients (ACM) with 22 controls.
- Measured serum/urine calcium, phosphorus, PTH, vitamin D, bone turnover markers (CTX, P1NP), and cytokines (RANK-L, OPG) at baseline and 3-6 months post-treatment.
Main Results:
- Acromegaly patients had lower PTH and higher phosphorus than controls.
- Bone turnover markers (CTX, P1NP) were elevated in acromegaly patients.
- Treatment decreased serum calcium, phosphorus, and CTX, while PTH increased.
Conclusions:
- Acromegaly causes PTH-independent calcium-phosphate disturbances and increased bone turnover.
- Treatment effectively reduced bone resorption (CTX) within six months.
- RANK-L/OPG ratio changes were inconsistent post-treatment.